Zacks Investment Research Downgrades Mazor Robotics Ltd. (MZOR) to Sell
Mazor Robotics Ltd. (NASDAQ:MZOR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “Mazor Robotics Ltd. is engaged in the development, production and marketing of medical devices for surgical procedures in the fields of orthopedics and neurosurgery. It offers Renaissance(TM), a surgical robotic system to conduct spine surgeries with less radiation. The company operates in the United States, Eastern Europe, Western Europe and Asia. Mazor Robotics Ltd. is based in Caesarea, Israel. “
Other equities research analysts have also recently issued reports about the company. B. Riley began coverage on Mazor Robotics in a research note on Tuesday, October 11th. They issued a “neutral” rating and a $25.00 price target on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Mazor Robotics in a research note on Wednesday, July 13th. Barclays PLC upped their price target on Mazor Robotics from $16.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, July 14th. Finally, Standpoint Research began coverage on Mazor Robotics in a research note on Friday, July 8th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $26.25.
Shares of Mazor Robotics (NASDAQ:MZOR) opened at 22.89 on Friday. The stock’s 50 day moving average price is $23.40 and its 200 day moving average price is $18.53. The stock’s market capitalization is $496.09 million. Mazor Robotics has a 12 month low of $8.31 and a 12 month high of $26.55.
Mazor Robotics (NASDAQ:MZOR) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. Mazor Robotics had a negative return on equity of 42.30% and a negative net margin of 60.75%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $8.51 million. During the same period in the previous year, the firm earned ($0.05) earnings per share. The business’s revenue was up 6.4% compared to the same quarter last year. Analysts expect that Mazor Robotics will post ($0.71) EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the company. EAM Investors LLC bought a new stake in Mazor Robotics during the second quarter valued at approximately $2,348,000. Iguana Healthcare Management LLC increased its stake in Mazor Robotics by 384.6% in the first quarter. Iguana Healthcare Management LLC now owns 121,151 shares of the company’s stock valued at $1,507,000 after buying an additional 96,151 shares during the period. Candriam Luxembourg S.C.A. bought a new stake in Mazor Robotics during the second quarter valued at approximately $1,079,000. Menta Capital LLC increased its stake in Mazor Robotics by 81.9% in the first quarter. Menta Capital LLC now owns 37,482 shares of the company’s stock valued at $466,000 after buying an additional 16,879 shares during the period. Finally, Cookson Peirce & Co. Inc. bought a new stake in Mazor Robotics during the second quarter valued at approximately $192,000. 18.72% of the stock is currently owned by institutional investors and hedge funds.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.
Receive News & Stock Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related stocks with our FREE daily email newsletter.